Validation of a novel point of care testing device for sickle cell disease by Julie Kanter et al.
TECHNICAL ADVANCE Open Access
Validation of a novel point of care testing
device for sickle cell disease
Julie Kanter1,5*, Marilyn J. Telen2, Carolyn Hoppe3, Christopher L. Roberts4, Jason S. Kim4 and Xiaoxi Yang4
Abstract
Background: Sickle cell disease is one of the most common inherited blood disorders. Universal screening and
early intervention have significantly helped to reduce childhood mortality in high-resource countries. However,
persons living in low-resource settings are often not diagnosed until late childhood when they present with clinical
symptoms. In addition, confirmation of disease in affected individuals in the urgent care setting is limited in both
high- and low-resource areas, often leading to delay in treatment. All of the current diagnostic methods rely on
advanced laboratory systems and are often prohibitively expensive and time-consuming in low-resource settings.
To address this need, the Sickle SCAN™ test has been developed to diagnose sickle cell disease and sickle cell trait
at the point of care without electricity or advanced equipment.
Methods: This study was conducted to evaluate and validate the diagnostic accuracy of the Sickle SCAN™ test, a
novel point of care test for sickle cell disease. Thus, we describe the laboratory testing and clinical validation of the
Sickle SCAN™ test in individuals >1 year of age using capillary blood. The Sickle SCAN™ test was created using
advanced, qualitative lateral flow technology using capillary blood to identify the presence of hemoglobin A, S,
and C allowing for detection of results with the naked eye.
Results: Laboratory testing using venous blood demonstrated 99 % sensitivity and 99 % specificity for the
diagnosis of HbSS, HbAS, HbSC, HbAC, and HbAA. Seventy-one subjects underwent capillary blood sampling at
the point of care for further validation. This test detected the correct A, S, and C presence with an overall
diagnostic accuracy of 99 % at the bedside.
Conclusion: The Sickle SCAN™ test has the potential to significantly impact the diagnosis and treatment for
sickle cell disease worldwide as well as enhance genetic counseling at the point of care. Further validation
testing will be conducted in newborns in resource-poor settings in upcoming studies.
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Background
Sickle cell disease (SCD) is one of the most common
inherited blood disorders in the world. SCD is caused by
the inheritance of two copies of the gene encoding
hemoglobin S, a protein that results from a missense
mutation in the β-globin subunit of hemoglobin A, or
the co-inheritance of the gene for hemoglobin S and
another abnormal or nonfunctional hemoglobin gene
[1]. Resulting erythrocytes are both unstable, leading
to excessive hemolysis, and abnormal, leading to
inflammation and vascular occlusion. Patients with SCD
have a multitude of complications, including pain, infec-
tions, stroke, acute chest syndrome (sickling and occlu-
sion within the pulmonary vasculature), and multi-organ
damage [2]. However, improvements in early diagnosis
and enhanced preventive care treatment in high-resource
countries has led to a dramatic improvement in child-
hood survival and increase in average lifespan of affected
individuals [3].
Many of the current improvements in treatment of
persons with SCD are the direct result of newborn
screening, which became universal in the United States
15 years ago [4]. Early diagnosis allows for the initiation
of prophylactic antibiotics as well as education of
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affected families on the importance of immediate evalu-
ation for children with symptoms of complications.
However, many low-resource countries in which SCD is
far more prevalent remain unable to provide universal
newborn screening, and affected children may not be
diagnosed until they present with symptoms. In addition
to the financial limitations of newborn screening, some
countries with relatively high incidences of SCD are also
limited by governments that may not recognize or agree
with the importance or utility of early testing.
Even in the United States, there remain many barriers
to care for persons with SCD. Pain is the hallmark
symptom of SCD and is the primary reason for which
affected patients seek care [5]. Adult persons with SCD
often rely on urgent care services due to a paucity of
trained and available specialty providers. In many com-
munity hospitals and rural areas, physicians may not
have the capability to diagnose affected individuals or
confirm disease in patients seeking urgent care. Even
when testing is available, results are often delayed and
not available until after patients have left the hospital
setting. This inability to validate disease status may lead
to delay in treatment for affected patients or use of treat-
ment in patients not actually affected by SCD.
The validation of a simple, rapid, electricity-free bed-
side test for SCD could transform clinical care for af-
fected persons in both low-income developing countries
and urgent care settings. The goal of this study was to
test the diagnostic accuracy, including the sensitivity,
specificity, and limit of detection (LoD) of this novel
testing device (Sickle SCAN™) in the laboratory, and
confirm the feasibility and validity of the test when used
at the bedside. It was important that the results demon-
strate that the new device is easy to use, can be per-
formed with capillary blood (finger stick), and that
results are easily viewed at the point of care (POC).
Methods
Design of testing device
The Sickle SCAN™ test was designed as a rapid, highly
sensitive test. It was created using advanced, qualitative
lateral flow technology to identify sickle cell disorders of
hemoglobin A, S, and C allowing for detection of results
with the naked eye in the POC setting. The test was spe-
cifically developed to allow for the confirmation of sickle
cell trait (HbAS) and SCD in persons with HbSS, HbSC,
HbSβ0, and HbSβ+ genotypes.
The test requires 5 μL of blood added to a provided
buffer-loaded module designed to release hemoglobin by
lysing erythrocytes. The resulting hemolyzed solution is
dropped onto the sample inlet of the Sickle SCAN™ cart-
ridge. The treated sample flows through the test cart-
ridge in order to interact with antibody-conjugated
colorimetric detector nanoparticles and travel to the
capture zones (identified by lines on the device). A
total of four detection lines are possible, including
hemoglobin variants A, S, C, and a control line
(which confirms the test is functioning). Samples
containing two hemoglobin variants (such as com-
pound heterozygotes) will have both hemoglobin var-
iants detected (Fig. 1).
Test principle
The Sickle SCAN™ assay employs the sandwich format
chromatographic immunoassay approach for the qualita-
tive measurement of human HbA, HbS, and HbC in
whole blood samples. A mouse monoclonal antibody
(MsxHb-15001, BioMedomics, Inc., Durham, NC, USA)
against the C-terminus of human hemoglobin α-chain is
used as the detection antibody. This detection antibody
is conjugated to blue colored nanoparticles (BMBB-32-
14001, 300 nm, BioMedomics, Inc.). Three polyclonal
antibodies against the initial N-terminal amino acid
sequence (BioMedomics, Inc.) of human sickle cell
hemoglobin (HbS), human hemoglobin C (HbC), and
adult normal hemoglobin (HbA) are used as capture
antibodies on test lines. A separate goat anti-mouse IgG
(H&L) antibody (GtxMu-003-E, ImmunoReagents, Inc.,
Raleigh, NC, USA) is used as the capture antibody to
form the control line.
As the test sample diffuses through the absorbent test
strip, the antibody-conjugated colorimetric detector
Fig. 1 Sickle SCAN™ test performance
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nanoparticles bind to the hemoglobin in the specimen,
forming an antibody-antigen complex. The specimen
then migrates across a membrane toward three test lines
containing HbA, HbS, and HbC antibodies to selectively
detect the presence of each Hb. The specific complex
with each Hb is captured at the test line with the corre-
sponding antibody and produces a blue colored band.
Excess conjugate will flow past the test lines and be cap-
tured on the control line. Therefore, to serve as a pro-
cedural control, a colored band will always appear at the
control line region if the proper volume of sample has
been added and membrane wicking has occurred. Once
the test has run and the control line appears, the
presence of any of those test lines indicates that the re-
spective hemoglobin is present in the blood. This allows
us to identify persons with hemoglobin A, sickle trait
(AS), HbSS, and HbSC disease. However, the LoD of
hemoglobin A (40 %) is higher than that of hemoglobin
S (2 %). This was an intentional design in order to en-
sure persons with HbSβ+ were identified with sickle cell
disease (although they are seen with this test as HbSS)
and still differentiate sickle cell trait (HbAS). As a result
of this distinction the intensity of the test lines does not
correlate in this initial Sickle SCAN™ test to the quantity
of the specific hemoglobin. In accordance, the test is
not designed to identify less common hemoglobin
variants (such as hemoglobin Constant Spring, hemoglobin
O-Arab, or others). Thus, results indicating hemoglobin A
alone is not diagnostic and further testing should be
considered in the context of an individual’s ethnic
background.
Design of testing device
In an effort to improve rapid test specificities and sen-
sitivities, this test was developed using advanced, quali-
tative lateral flow technology and detection requiring
only the naked eye. This Sickle SCAN™ test was created
to identify sickle cell disorders of hemoglobin A, S,
and C.
Sickle SCAN™ is a qualitative lateral flow immunoassay
that tests for the presence of hemoglobin A, S, and C
(Fig. 2). The kit includes the immunoassay, capillary
sampler, and pretreatment buffer. Five microliters of
sample is taken using the capillary sampler (Fig. 3a) and
then diluted in the pretreatment buffer (Fig. 3b). Once
diluted, five drops of the sample are dispensed onto the
immunoassay and the test is read after 2 minutes
(Fig. 3c).
Ex vivo laboratory testing methods
Patient samples were obtained from venipuncture per-
formed at the Medical University of South Carolina
(Charleston, SC, USA), Duke University (Durham, NC,
USA), and Children’s Hospital Oakland (Oakland, CA,
USA). The collection and use of these samples for test
development were approved by the local institutional
review boards (IRBs) in each institution above. Patients
were recruited from the regular SCD clinic populations.
Samples were collected in EDTA and kept at room
temperature for shipment to BioMedomics, Inc. Testing
occurred within 4 weeks of sample receipt. Those who
had received a blood transfusion within the last 60 days
were excluded from analysis.
Five microliters of venous sample (taken from the
EDTA-stored samples) were mixed in 1 ml of hemoglobin
solubility buffer (used to lyse erythrocytes) designed spe-
cifically for this device. The sample was mixed by inver-
sion for 20 seconds and then five drops (using the
designated dropper) of hemolyzed solution were dropped
onto the inlet to the Sickle SCAN™ testing platform. Ten
minutes elapsed prior to quantification of the test line
Fig. 2 Schematic illustration of the design of Sickle SCAN™ strip with
absorbent pad, control line, HbA line, HbS line, HbC line, conjugate
pad, sprayed conjugates, and sample pad
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color intensity. Data collection and reference standards
were planned as per the test principle prior to the
index test.
The initial quantification of the Sickle SCAN™ test line
color intensity was accomplished by removing the assay
strip from the device cartridge and scanning it using a
portable flatbed scanner (CanoScan LiDE210, Canon,
Melville, NY, USA). The image was then analyzed using
a custom-coded algorithm (MATLAB, MathWorks,
Cambridge, UK) to determine the color intensity of the
test lines. The quantitative analysis of the test line inten-
sities was determined by the RGB color model values of
the image at the test line positions. The software auto-
matically determined the test line positions by searching
for the control line, present on all tests, and measuring a
set distance to the next test line position. An inten-
sity cutoff was determined to distinguish between
positive and negative results for each line. Sickle
SCAN™ was compared to either hemoglobin electro-
phoresis (HYDRASYS acid assay, Sebia, Norcross,
GA, USA) or high performance liquid chromatography
(HPLC) for each sample using standard guidelines. Con-
firmatory testing using the above techniques was per-
formed individually at the designated institutions. The
results of these confirmatory tests are thus described
interchangeably as the gold standard diagnostics. Of note,
a scanner is not required for the POC test but was used
here for confirmation during analysis.
Limit of detection (LoD)
The LoD is the minimum percent of a specific Hb, that
is, HbA, in which the indicator can be read. The percent
Hb is the percentage of the specific hemoglobin out of
the total Hb concentration. The LoD for the HbA indi-
cator was tested in samples ranging from 0–60 % HbA
in increments of 10 %. The LoD for the HbS was tested
with samples ranging from 0–40 % HbA in varying in-
crements, and the LoD for the HbC indicator was tested
with samples containing 0–10 % HbC in increments of
2 %. The samples for the HbA, HbS, and HbC LoD stud-
ies were prepared, respectively, by mixing HbA, HbS,
and HbA + C standards with either HbS or HbA stan-
dards to create the desired specific Hb percentages. Each
sample was loaded onto the Sickle SCAN™ assay and
allowed to run for 10 minutes.
Interfering factors
Whole blood samples with BSA at concentrations of 0–
100 mg/mL, penicillin at concentrations of 0–500 μg/mL,
hydroxyurea at concentrations of 0–75 μg/mL, bilirubin at
concentrations of 0–2.5 μg/mL, and cholesterol at concen-
trations of 0–4 mg/mL were tested in this interference
study.
Capillary testing methods
All patients signed written consent to participate in test-
ing by finger stick at the POC. For pediatric patients
under 18 years of age, informed consent to participate in
the study was obtained from their parent or guardian.
IRB approval was obtained from the Medical University
of South Carolina (MUSC) to conduct a pilot trial using
this POC test device in patients with SCD and their fam-
ily members followed at the MUSC SCD clinic. All SCD
providers in the clinic were trained in reading the testing
device prior to the initiation of testing.
Subjects of all ages were included in the trial. Accord-
ing to the approved IRB protocol, all included patients
with SCD had to have a current HPLC hemoglobin vari-
ant result. In most infants between 6–12 months of age,
HPLC is not assessed routinely after the initial confirma-
tory assessment. Thus, although the LoD for both HbS
and HbC (1 % and 2 %, respectively) discussed above in
the ex vivo study demonstrates that the test will likely be
useful in newborn children, they were not included in
this validation study and a follow-up study in neonates
will be undertaken. Those who had received a blood
transfusion within the last 60 days or whose hemoglobin
genotype was not previously known were excluded. Pa-
tients receiving hydroxyurea therapy were included. At
the time of consent, 71 patients met inclusion and exclu-
sion criteria based on their history and were consented
to undergo testing. Blood was obtained from the finger
Fig. 3 Sickle SCAN™ test procedure. a Five microliters of finger stick sample is taken using the capillary sampler. b The sample is then mixed with the
pretreatment buffer. c Five drops of the diluted sample are then dispensed onto the test well. Figure reproduced with permission from BioMedomics
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pad using a standard lancet for capillary testing. Five mi-
croliters of blood was collected using the capillary sam-
pler provided in the testing kit and added to the
buffered loaded module. After inverting the module × 3,
five drops of hemolyzed sample were dropped onto the
inlet of the Sickle SCAN™ cartridge. Results were read
within 120 seconds. The Sickle SCAN™ test result was
determined after visual inspection sequentially by two
independent providers who determined the results sep-
arately without reference to one another. Due to timing,
the initial provider read the test at 2 minutes and the
second provider read the test between 4–10 minutes
after sample had been added. In affected patients, the
first provider had knowledge of the patient’s genotype
prior to testing. However, the second provider was
always blind to the sample being tested. On average, all tes-
ters reviewed each sample within 5 minutes of testing.
Results
Ex vivo laboratory testing
Ex vivo laboratory testing results
Sickle SCAN™ results were compared to gold standard
testing by either hemoglobin electrophoresis (HYDRASYS
acid assay, Sebia) or HPLC (Finnigan Surveyor,
Thermo Electron Corporation, Waltham, MA, USA,
and VARIANT II TURBO, BioRad, Hercules, CA, USA)
using standard guidelines at the institutions where samples
were collected. Patient samples (n = 137) were collected
and measured in duplicate (on the same sample) using
Sickle SCAN™ and compared to the gold standard diagnos-
tic test obtained at the institution where the sample initi-
ated (Table 1).
Limit of detection (LoD) results
The Sickle SCAN™ LoD for hemoglobin A, S, and C was
determined to be 40 %, 1 %, and 2 %, respectively
(Additional file 1: Tables S1–S3). The LoD for HbA was
set higher than for HbS and HbC both to allow: a) pa-
tients with HbSβ+ who usually have up to 25 % HbA to
be diagnosed as HbS using Sickle SCAN™, and to be dif-
ferentiated from those with HbAS who have >40 % HbA
and will be visualized as ‘AS’; and b) to ensure the LoD
for HbS and HbC were small enough to make this test
useful in the neonatal period.
Interfering factors
Results demonstrated that Sickle SCAN™ had no inter-
ference by the following substances at the concentra-
tions indicated: protein (BSA) 100 mg/mL; penicillin
250 μg/mL; hydroxyurea 75 μg/mL; bilirubin 2.5 mg/mL;
and cholesterol 4 mg/mL (Additional file 1: Table S4–S8).
Reading time factor
The optimal time to interpret the results was determined
using one clinical AA sample and one clinical SC sam-
ple. These tests were run together and scanned using a
portable flatbed scanner (CanoScan LiDE210, Canon)
similar to the method used for the ex vivo laboratory
testing. The tests were scanned for 5 minutes through
24 hours after the samples were loaded and analyzed
using a custom-coded algorithm (MATLAB, MathWorks).
The quantitative analysis of the test line intensities
was determined by the RGB color model values of the
image at the test line positions (shown in Additional
file 1: Table S9). To read the tests under 5 minutes a
separate study was conducted with eight clinical samples
(two AA, two AS, two SC, and two SS) read by three in-
dividuals that were not provided with any identifying in-
formation on the samples. Their interpretation of the
results were recorded and compared to the diagnosis of
each clinical sample (Additional file 1: Table S10). The
combined results from both of these reading time
studies suggest that the Sickle SCAN™ can be read
between 2 minutes and 24 hours after the sample
has been loaded.
Capillary testing at the point of care (POC)
Seventy-one subjects with HbAA, HbAS, HbAC, HbSS,
HbSβ+, HbSD, or HbSC were included. Patients ranged
in age from 5 weeks to 72 years. Included in this sample
were 21 children (age <21 years, mean age of 13.5 years)
and 50 adults (>22 years. Patients were recruited and
tested from November 2014 to June 2015. There were
no adverse events from the capillary sampling. Sample
results are shown below with confirmed genotypes
(Table 2). There was 100 % concordance among pro-
viders interpreting the results.
The Sickle SCAN™ test performed favorably with one
false negative result in which the test read AS (sickle cell
trait) in a patient with confirmed HbSD disease). In 71
subjects, this test detected the correct A, S, and C pres-
ence with an overall diagnostic accuracy of 99 %
(Table 3).
Table 1 Sickle SCAN™ performance compared to genotypes
identified by gold standard diagnostic testing
Sickle scan test result
SS AS SC AC AA Total
HbSS 42 0 0 0 0 42
HbAS 0 24 0 0 0 24
HbSC 0 0 37 0 0 37
HbAC 0 0 0 4 0 4
HbAA 0 0 0 0 30 30
Total 42 24 37 4 30 137
Specificity >99 % >99 % >99 % >99 % >99 % >99 %
Sensitivity >99 % >99 % >99 % >99 % >99 % >99 %
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Discussion and conclusions
According to the authors’ knowledge, there is no other
similar SCD diagnostic device currently on the market.
A variety of POC devices for the diagnosis of SCD are
currently in development and testing, but the Sickle
SCAN™ employs lateral flow immunoassay technology,
which favors its utility for large-scale screening efforts in
low-resource settings. In addition, other tests in develop-
ment have not successfully been able to produce a test
that can distinguish HbSS, HbAS, and HbSC, which
makes this new device substantially more useful.
The Sickle SCAN™ differs from previous tests for de-
termining the presence or absence of HbS and/or HbC
in whole blood samples and offers significant advantages
not realized in prior applications. For example, solu-
bility testing methods such as SICKLEDEX® (Streck,
Inc., Omaha, NE, USA) and concentrated phosphate
buffer are simple and inexpensive, but do not differ-
entiate between sickle cell disease (including HbSS,
HbSβ0-thalassemia, HbSβ+-thalassemia, and HbSC) and
sickle trait (HbAS). The methods are based on HbS
polymerization (visible turbid suspension) in the presence
of a concentrated phosphate buffer solution. All positive
test results require further evaluation by hemoglobin elec-
trophoresis or HPLC when used for patient screening.
These deficiencies are overcome by this novel testing
device.
In an optimized solubility testing method, instead of
measuring turbidity, the characteristic blood stain
formed on a paper-based assay becomes an active elem-
ent [6] and the polymerized HbS is entangled by the
paper fibers. The soluble hemoglobin will continue to
spread on the paper and, because it is colored, the assay
read out uses the red color count in the region of the
polymerized hemoglobin and soluble hemoglobin. The
visual signals need to be analyzed by a scanner to correl-
ate the blood stain pattern with the concentration of
HbS present. But this assay cannot accurately distinguish
between individuals with HbAS (trait) and HbSC
(disease) since they have similar HbS concentrations. In
a person with HbSC, the presence of HbC enhances the
pathogenic properties of HbS by inducing dehydration
and therefore sickling at a significant level that would
not take place in a person with similar levels of HbS
without HbC. Here again, these deficiencies are over-
come by Sickle SCAN™.
A hemolysis monitoring assay in non-electrolyte solu-
tions [7] has been proposed to distinguish red blood cells
from HbSS and HbAS individuals based on the altered
properties of the RBC membrane resulting from HbS
polymerization. However, an hour of incubation time, as
well as a requirement for the use of tonometer and optical
density measurements, make such a test difficult to be
used at the POC or in low-resource areas that do
not have the capacity to support these instruments.
The recent development of a cell density-based aque-
ous multiphase system requires a drop of whole blood,
which goes into a capillary tube filled with three differ-
ent polymeric aqueous solutions. After centrifugation in
a small, battery-operated instrument, sickle cells are sep-
arated from normal red blood cells, based on differences
in their cell density. The isolated sickle cell fraction then
needs to be detected by a simple optical reader. The re-
quired use of centrifuge and optical reader challenges
the simplicity of this POC test. Additionally, HbAA
(normal) and HbAS (trait) have the same performance
in this system and cannot be distinguished [8]. Once
again these deficiencies are overcome by the Sickle
SCAN™ test demonstrated here.
The innovative design for Sickle SCAN™ described
above provides: 1) high specificity to identify HbS, HbC,
and HbA, even in the presence of up to 30 % HbF (as in
persons on hydroxyurea) or HbA2; 2) high sensitivity to
simultaneously detect HbS, HbC, and HbA, even in
anemic patients; and 3) an unprecedented capacity to
differentiate SCD (homozygous HbSS, heterozygous




23 S 20 confirmed HbSS
2 confirmed HbSβ0
1 confirmed HbSβa,b
14 SC 14 confirmed HbSC
21 AS 17 confirmed or previously known
HbAS (trait)
3 confirmed HbSS with recent transfusionb
1 confirmed HbSDc
3 AC 3 persons with known HbAC
8 A 8 persons known without HbC or HbSd
2 C 3 confirmed with HbCC
aAs per the purposeful test design, persons with HbSβ+ appear as HbSS using
this test. This sample contained 24 % hemoglobin A; bpersons with HbSS that
were found to have been transfused based on electrophoresis and further
investigation after testing; cerroneous result of HbAS in person with HbSD;
dpersons noted to have HbA were known β-thalassemia carriers in two cases.
Definitive electrophoresis was not performed in six cases but newborn screening
reports were reportedly normal in all six persons
Table 3 Sensitivity and specificity of Sickle SCAN™ compared to
known patient genotypes
Sensitivity (95 % CI) Specificity (95 % Cl)
SCD (HbSS, HbSC, HbSβ+-thal,
HbSβ0-thal)
100 % (91–100) 100 % (90–100)
Sickle trait (HbAS) 100 % (85–100) 98 % (90–100)
C trait (HbAC) 100 % (44–100) 100 % (95–100)
Normal (HbAA) 100 % (68–100) 100 % (94–100)
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HbSC, and HbSβ-thalassemia) from sickle cell trait
(heterozygous HbAS) and normal adult hemoglobin
(HbAA). Of note, it should be clarified that the ability to
differentiate persons with HbAS and HbSβ+ using Sickle
SCAN™ is subtle. Because individuals with HbSβ+ usually
have less than 25 % HbA, they will appear as if they have
HbSS disease using this test (compared to those with
HbAS who have >40 % HbA). This difference also eluci-
dates the reason for which the LoD for HbA was set at
40 % for this test. In contrast to the other aforemen-
tioned POC tests for SCD, this test does not require
electricity, equipment, or a skilled nurse or physician to
draw blood. In contrast, the test is easy to perform and
results are read visually with the naked eye using the de-
tection lines on the device.
Thus, the Sickle SCAN™ will be the first POC device
that is able to diagnose and differentiate the most com-
mon forms of SCD and trait as well as HbC disease and
trait. It is designed as a sensitive, rapid and low-cost test
to be used as the primary diagnostic tool for SCD and
sickle trait in sub-Saharan Africa, India, and other
regions of the developing world. The company has
already received CE mark approval and has commenced
commercialization in these regions.
Currently, there are two noted limitations in the Sickle
SCAN™ test.
1. At present, the LoD for hemoglobin A is set at 40 %.
This was configured in order to capture persons
with HbSβ+ disease (which are seen as HbS alone on
the test results). However, it is important that testers
do not conflate the weak HbA line seen in persons
with HbAS as a low quantity hemoglobin. The
degree of intensity of the line does not correlate
with the quantity of hemoglobin. Thus, results
demonstrating bands at HbS and HbA are consistent
with sickle cell trait despite the fact that the band at
S is darker than the band at A. This limitation is
easily overcome with proper teaching of the test.
2. The Sickle SCAN™ test only shows hemoglobin A, S,
and C, as described. Thus, the test cannot identify
thalassemia carriers, a condition which can impact
genetic counseling. Additionally, the test cannot
identify all hemoglobin variants but instead is
heavily reliant on the most common. Thus, results
of hemoglobin A cannot be definitively correlated
to the HbAA genotype based solely on the results
of this test.
Further studies using the Sickle SCAN™ device are
already in progress for both community-based sickle cell
disease/sickle cell trait testing as well as for the diagnosis
of SCD in the newborn period, which is of crucial im-
portance. We believe this test will significantly enhance
the ability to diagnose patients in low-resource areas
quickly and easily in order to enhance preventative care
treatment. The Sickle SCAN™ test has already obtained
CE mark approval in Europe.
Key points
This article describes the clinical validation for a novel
point of care testing device, Sickle SCAN™ for the rapid
diagnosis of sickle cell disease.
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